Photo credit: The Mayo Clinic
With a focus on Alzheimer’s disease prevention research, GHR Foundation funded a groundbreaking Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study which may help identify people who are highest risk to develop the disease. This research will also identify treatments – and when to best administer them – to slow or prevent Alzheimer’s. Long-term, the Foundation hopes the A4 study and complementary research will result in FDA approval for Alzheimer’s prevention therapies.
The A4 study team is continuing to develop the clinical partnerships necessary to study 1,000 patients and has created tools to share background with potential participants. GHR Alzheimer’s advisory board member and lead A4 researcher Dr. Reisa Sperling explains the research and how people can get involved in the research in a recent YouTube video.
GHR looks forward to learning more about the impact of A4 on early detection and treatment of Alzheimer’s disease.
The A4 study team is continuing to develop the clinical partnerships necessary to study 1,000 patients and has created tools to share background with potential participants. GHR Alzheimer’s advisory board member and lead A4 researcher Dr. Reisa Sperling explains the research and how people can get involved in the research in a recent YouTube video.
GHR looks forward to learning more about the impact of A4 on early detection and treatment of Alzheimer’s disease.
RSS Feed
